Diabetes Mellitus Clinical Trial
Official title:
Cerebrovascular Effects of the Use of Alpha-stat or pH-stat Management of Cardiopulmonary Bypass
Type 2 diabetes mellitus (T2DM) poses a significant burden on the patients and the health
care system. The increasing number of surgery performed in elderly population results in an
increased number of perioperative T2DM-related adverse effects. T2DM has a prevalence of
30-40% in a population undergoing cardiovascular surgery. Cardiac surgery, especially
cardiopulmonary bypass (CPB) is also known to deteriorate cerebral oxygenation.
Furthermore, acid-base balance of patients undergoing CPB can be managed using two main
regimes: alpha-stat and pH-stat. The use of pH-stat acid-base management involves maintaining
the patient's temperature-corrected pH at a constant level (7.40) and maintaining normocapnia
(pCO2 of 40 mmHg). Alpha-stat acid-base management on the other hand is performed by
maintaining the ionization state of histidine by keeping the pH stable when a standardized
temperature of 37C is used. Therefore, while a constant pH (7.40) and normocapnia (pCO2 of 40
mmHg) are targeted when measured at 37C, the hypothermia applied during CPB will result in a
lower pCO2 and in a relative respiratory alkalosis. Previous studies investigating alpha-stat
and pH-stat managements demonstrated increased jugular venous oxygen concentrations when
pH-stat management was applied.
Therefore, our study is aimed at characterizing the effects of an alpha-stat or pH-stat
acid-base management regime on the cerebral oxygenation, parameters of regional cerebral
oxygen supply and demand during and following CPB in diabetic patients. These parameters
include regional cerebral tissue oxygen saturation (rSO2), central venous oxygen saturation
ScvO2) and the physiological saturation gap between ScvO2 and rSO2 (gSO2).
One hour before the surgery, patients are premedicated with lorazepam (per os, 2.5 mg).
Induction of anaesthesia is achieved by iv midazolam (30 μg/kg), sufentanyl (0.4-0.5 μg/kg),
and propofol (0.3-0.5 mg/kg), and iv propofol (50 mg/kg/min) is administered to maintain
anaesthesia. Intravenous boluses of rocuronium (0.6 mg/kg for induction and 0.2 mg/kg every
30 minutes for maintenance) is administered iv to ensure neuromuscular blockade. A cuffed
tracheal tube (internal diameter of 7, 8, or 9 mm) is used for tracheal intubation, and
patients are mechanically ventilated (Dräger Zeus, Lübeck, Germany) in volume-controlled mode
with decelerating flow. A tidal volume of 7 ml/kg and a positive end-expiratory pressure of 4
cmH2O are applied, and the ventilation frequency is adjusted to 12-14 breaths/min to maintain
end-tidal CO2 partial pressure of 36 38 mmHg. Mechanical ventilation is performed with a
fraction of inspired oxygen of 0.5 before CPB, and it is increased to 0.8 after CPB. As a
standard part of the cardiac anaesthesia procedure, oesophageal and rectal temperature probes
are introduced, and a central venous line is inserted into the right jugular vein. The left
radial artery is also cannulated to monitor systolic, diastolic and mean arterial (MAP) blood
pressures and arterial blood gas samples.
The membrane oxygenator is primed with 1,500 ml lactated Ringer's solution prior to CPB.
Intravenous heparin (300 U/kg) is injected into the patient, to achieve an activated clotting
time of 400 s during CPB procedures. During CPB, mild hypothermia is allowed, the mechanical
ventilation is stopped, and the ventilator is disconnected without applying positive airway
pressure. Before restoring ventilation, the lungs are inflated 3-5 times to a peak airway
pressure of 30 cmH2O to facilitate lung recruitment.
After securing arterial and peripheral venous lines and placement of NIRS and entropy
sensors, data collection is initiated immediately before anesthesia induction in all groups
of patients. Since catheterization of the jugular vein is scheduled after anesthesia
induction, ScvO2 and gSO2 data are not available at the first protocol stage. After induction
and before surgical incision, all measurements are repeated. The whole data set is registered
at the beginning of CPB after clamping the aorta and 5 min before the end of CPB. The final
stage of the protocol is allocated to the end of the operation after sternal closure. All
invasive (i.e. arterial and venous blood gas) and non-invasive (i.e. NIRS) data are
registered simultaneously at each protocol stage.
Sample sizes are estimated to enable the detection of a 10% difference in the primary outcome
parameter gSO2 that we considered clinically significant. Accordingly, sample-size estimation
based on an ANOVA test with 4 groups of patients (diabetic and control patients undergoing
CPB with alpha-stat or pH-stat acid-base regime) indicated that 100 patients were required in
each group to detect a significant difference between the protocol groups.
Two-way repeated measures ANOVA with the inclusion of an interaction term is used for all
measured variables with the protocol stage as within-subject factor (protocol stages) and
group allocation as between-subject factor to establish the effects of T2DM and the acid-base
management regime on the parameters of cerebral oxygenation. At half-way of the data
collection, an interim analyses will be performed and the further data collection will be
proceeded based on the results of this analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |